title: Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.
authors.affiliation: Department of Gynecology and Obstetrics, University of Cologne, Germany. thomas.schoendorf@medizin.uni-koeln.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Schöndorf
authors.forename: Markus
authors.initials: M
authors.lastname: Hoopmann
authors.forename: Mathias
authors.initials: M
authors.lastname: Warm
authors.forename: Rainer
authors.initials: R
authors.lastname: Neumann
authors.forename: Anke
authors.initials: A
authors.lastname: Thomas
authors.forename: Uwe-Jochen
authors.initials: UJ
authors.lastname: Göhring
authors.forename: Carsten
authors.initials: C
authors.lastname: Eisberg
authors.forename: Peter
authors.initials: P
authors.lastname: Mallmann
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D009362:Neoplasm Metastasis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D000068878:Trastuzumab; D014781:Viscera
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018396:Mucin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab